S

Sanofi

Global pharma company; vaccines and R&D

Customer Engagement Manager - Vaccines MYSG

Full-TimeUpdated on 10/15/2026Deadline 10/30/26
No salary listed
Mid, Senior
Bachelor's
Petaling Jaya, Selangor, Malaysia
In Person
Growth & MarketingGrowth Marketing

About the job

Requirements
  • A bachelor's degree in Marketing, Business Administration, or a related field.
  • Three to five years of experience.
  • Deep understanding of the pharmaceutical industry's regulatory environment, market dynamics, and customer engagement.
  • Understanding of healthcare professionals' preferred experiences, key clients, and the end-to-end customer journey, including customer touchpoints from initial awareness through post-purchase support.
  • Knowledge and experience with innovative methodologies such as Scrum, lean startup, nudge, and design thinking.
  • Experience with digital engagement tools, artificial intelligence applications for customer insights, and Agile methodologies.
  • Fluency in the primary language or languages of the country or countries of operation.
  • A proven track record of developing and implementing customer engagement strategies that improve customer satisfaction and loyalty.
  • Experience leading customer engagement or relationship management initiatives, preferably in healthcare or pharmaceuticals, including delivering customer experiences and understanding engagement channels and tools.
  • Hands-on experience leading digital transformation projects that enhance customer engagement through artificial intelligence and data analytics.
  • Experience effectively leading cross-functional teams and adapting strategies in a dynamic environment.
  • Experience ensuring customer engagement activities comply with local regulations and ethical standards, particularly in healthcare or pharmaceuticals.
  • Ability to leverage insights and data to develop and execute customer engagement strategies.
  • Ability to lead by example and foster a customer-centric culture within the team and organization.
  • Commitment to understanding and prioritizing customer needs and preferences, with experience implementing strategies that improve customer satisfaction and loyalty.
  • Ability to adapt strategies based on customer feedback and market changes and to develop new ways to engage customers.
  • Ability to collaborate with brand leads and cross-functional teams to align customer engagement and brand strategies.
  • Proficiency in digital engagement tools and platforms and understanding of how artificial intelligence can enhance customer interactions and personalize communications.
  • Ability to adapt to Agile ways of working and use Agile methodologies for cross-team projects and initiatives.
Responsibilities
  • Develop a deep understanding of the customer engagement journey and create an omnichannel engagement blueprint.
  • Lead customer engagement planning and actions that prioritize meaningful direct interactions, leverage insights, and align with business objectives to drive engagement and satisfaction.
  • Develop detailed call plans aligned across brands, defining the frequency, messaging, and objectives for each channel so customer communications are consistent, personalized, and strategically timed.
  • Review and track omnichannel key performance indicators and propose adjustments or improvement plans.
  • Engage customers across multiple platforms using an omnichannel approach, ensuring consistent and personalized communications.
  • Collaborate with the MCO Brand Lead to contribute customer insights, competitive information, and market trends to MCO and global strategies.
  • Work with the sales force and key account managers, where applicable, to optimize processes and systems and provide a seamless customer journey.
  • Collaborate on and support go-to-market exercises.
  • Work with the cross-functional team using Agile practices where possible.
  • Adopt digital transformation and Agile methodologies, including data and artificial intelligence, to accelerate and scale new operating models.
  • Adapt and evolve ways of working while delivering business results and avoiding business disruption.
  • Promote global-local and cross-functional ways of working by leveraging centralized and standardized frameworks, including GTMC and MCO teams.
  • Ensure alignment with MCO strategies and foster collaboration with MCO teams.
Desired Qualifications
  • Experience managing projects using Agile methodologies is a plus.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)